# Meet the experts: Cardiogenic Shock

## Inotropes: effects on the heart, the microcirculation and other organs

**ACCA Masterclass 2017**

Alessandro Sionis
Director Acute & Intensive Cardiac Care Unit
Hospital de la Santa Creu I Sant Pau
Universitat de Barcelona
Spain

WE ARE THE ESC

Acute Cardiovascular Care Association ACCA
A Registered Branch of the ESC

EUROPEAN SOCIETY OF CARDIOLOGY®

# Disclosures (last 5 years)

- Speaker: Abiomed, Maquet, Novartis, Orion-Pharma
- Clinical trials: Cardiorentis, Novartis, Orion-Pharma
- Research grants: Novartis, Orion-Pharma
- Royalties: No






*Adapted from 2016 ESC HF Guildeines*






*Adapted from 2016 ESC HF Guildeines*

| Definitions of Terms Used in Cardiogenic Shock Diagnosis | |
|---|---|
| **Term** | **Definition** |
| Symptoms/signs of congestion (left-sided) | Orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales (bilateral), peripheral oedema (bilateral). |
| Symptoms/signs of congestion (right-sided) | Jugular venous dilatation, peripheral oedema, congested hepatpmegaly, hepatojugular reflux, ascites, symptoms of gut congestionsymptoms of gut congestion. |
| Symptoms/signs of hypoperfusion | Clinical: cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure.<br>Laboratory measures: metabolic acidosis, elevated serum lactate, elevated serum creatinine.<br>Hypoperfusion is not synonymous with hypotension, but often hypoperfusion is accompanied by hypotension. |
| Hypotension | Systolic BP <90 mmHg |
| Hypoxaemia | Arterial PaO2 <80 mmHg (<10,67 kPa) |
| Acidosis | pH <7.35 |
| Elevated blood lactate | >2 mmol/L |
| Oliguria Urine output | <0.5 mL/kg/h |

# "Wet" & "Cold"

Systolic blood pressure <90 mmHg?

**YES**

- Inotropic agent
- Consider vasopressor in refractory cases
- Diuretic (when perfusion corrected)
- Consider mechanical circulatory support if no response to drugs

**NO**

- Vasodilators
- Diuretics
- Consider inotropic agent in refractory cases



*Adapted from 2016 ESC HF Guildeines*

# Targeted Medical Treatment in CS

Congestion (high or normal LVEDP)



Poor perfusion (low cardiac output)



# Microcirculation

The ultimate therapeutic goal in CS is to restore microcirculatory function
(adequate oxygen supply to sustain cellular function)





Active recruitment of microcirculation is essential
Sublingual perfused capillary density (PCD) imaging allows direct visualization of sublingual microcirculation



*Ince C. Crit Care Med 1999; 27:1369-1377*

# Microcirculatory Shutdown

- Increased oxygen consumption and impaired oxygen delivery and extraction due to microcirculatory shutdown and shunting
- During sepsis (and CS) microvasculature is the first to go and the last to recover

Before and after nitroglycerin




Orthogonal polarisation spectral imaging (OPS)






*Spronk PE. Lancet 2001; 360:1395-1396*

# Microcirculation in Cardiogenic Shock




Survival stratified according to quartile of baseline sublingual PCD









*den Uil CA. Eur Heart Jour 2010;31:3032-3039*

# Portrait of The Ideal Cathecolamine

- Pharmaceutically: non-toxic, stable preparation, compatible with other drugs, peripherally deliverable, easy titration (on-off effect), steady effect (no tachyphylaxis), metabolized independent of liver and renal function
- Pharmacodynamic properties: increases contractility, increases mean arterial pressure, maintenance of diastolic blood pressure, increases cardiac output, improves regional perfusion, no increase in myocardial oxygen consumption, no tachycardia, non-arrhythmogenic, suitable in pregnancy and paediatric populations
- Beneficial effect on hard clinical end-points (save lives)
- Cost effective

# What We Have…

- Increase myocardial oxygen consumption
- Increase myocardial ischaemia
- Can trigger arrhythmias (ventricular and supraventricular)
- Can cause infarct expansion
- Can worsen peripheral tissue perfusion and microcirculation
- No clear clinical benefit

# Currently Available Inotropes and Vasopressors

| Drug | Mechanism | Effect |
|---|---|---|
| Dobutamine | β1 (and β2) receptor | Inotropic, chronotropic, mild vasodilatation |
| Dopamine | $D_{1\text{-}2}$ (0.5 to 3 µg/kg/min), β1 (3-10 µg/kg/min) and α1 (>10 µg/kg/min) receptors | Dose dependent (inotropic, chronotropic, vasoconstriction) |
| Milrinone | Phosphodisterase 3 inhibitor | Inotropic, vasodilatation |
| Levosimendan | $Ca^{2+}$ sensitizer, ATP-dependent $K^{+}$ channels | Inotropic, vasodilatation |
| Noradrenaline | α1 (mild β1) | Vasocontriction |
| Adrenaline | α1, β1 and β2 | Inotropic (low dose), vasoconstriction (higher doses) |

# Levosimendan: SURVIVE Trial

ORIGINAL CONTRIBUTION

## Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure

### The SURVIVE Randomized Trial

- Randomized, double-blind trial comparing levosimendan versus dobutamine
- 1327 AHF patients with LVEF <30%, insufficient response to iv diuretics and: dyspnoea at rest or mechanical ventilation, oliguria, PCWP > 18 mmHg and/or CI <2.2 L/min/$m^2$
- Vey sick cardiogenic shock patients excluded



*Mebazaa A. JAMA 2007;297:1883-1891*

# Levosimendan: SURVIVE Trial




| No. at Risk | | | | | |
|---|---|---|---|---|---|
| Levosimendan | 664 | 608 | 586 | 525 | 462 |
| Dobutamine | 663 | 596 | 568 | 519 | 454 |



*Mebazaa A. JAMA 2007;297:1883-1891*

# Levosimendan: REVIVE Trial

JACC: Heart Failure
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 1, No. 2, 2013
ISSN 2213-1779/$36.00
http://dx.doi.org/10.1016/j.jchf.2012.12.004

CLINICAL RESEARCH

## Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

Milton Packer, MD,* Wilson Colucci, MD,† Lloyd Fisher, PHD,‡ Barry M. Massie, MD,§
John R. Teerlink, MD,§ James Young, MD,|| Robert J. Padley, MD,¶ Roopal Thakkar, MD,¶
Leticia Delgado-Herrera, RPH,¶ Jeffrey Salon, MD,¶ Chris Garratt, MB, CHB,# Bidan Huang, PHD,¶
Toni Sarapohja, MSC,# for the REVIVE Heart Failure Study Group

*Dallas, Texas; Boston, Massachusetts; Seattle, Washington; San Francisco, California; Cleveland, Ohio; Abbott Park, Illinois; and Espoo, Finland*

- Randomized, double-blind trial comparing levosimendan vs placebo (inclusion 2001-2004, published 2013)
- 600 AHF patients with LVEF <35% (CS excluded)
- Primary end-point changes in clinical status during first 5 days



*Packer M. J Am Coll Cardiol HF 2013;1:103–11*

# Levosimendan: REVIVE Trial







- Significant benefit in favour of levosimendan for primary end-point but increased risk of adverse cardiovascular events
- Significant drop in BNP but no effect on mortality



*Packer M. J Am Coll Cardiol HF 2013;1:103–11*

# Levosimendan in Cardiogenic Shock

- Small (32 patients), single center, open label, randomized trial









*Fuhrmann JT. Crit Care Med 2008; 36:2257-66*

# Noradrenaline

Comparison of norepinephrine and dopamine in the treatment of shock









*De Backer D. N Engl J Med 2010; 372:779*

# Effect of AHF Treatment on Mortality: Propensity Score Analysis




*Mebazaa A. Intensive Care Med. 2011 Feb;37(2):290-30*

# Inodilators in Cardiogenic Shock: Propensity Score Analysis

## ALARM-HF, EFFICA, AHEAD Registries (988 CS patients)




| | n | HR |
|---|---|---|
| PS Weighting | 988 | 0.66 |
| No ACS | 374 | 0.64 |
| ACS | 614 | 0.68 |
| ALARM–HF | 297 | 0.65 |
| EFICA | 572 | 0.61 |
| AHEAD | 119 | 0.66 |




*Combined Regimen* **Better**

*Perracchio R. PLoS One. 2013;8(8):e71659*

# Use of Inotropes and Vasopressors in the CardShock Study

| Vasoactive | All (n=220) | ACS (n=178) | non-ACS (n=42) | p |
|---|---|---|---|---|
| **Vasopressors** | | | | |
| **Noradrenaline** | **75%** | 76% | 69% | **NS** |
| **Adrenaline** | **21%** | 23% | 14% | **NS** |
| **Dopamine** | **26%** | **29%** | **12%** | **0.03** |
| **Vasopressin/Terlipressin** | **4%** | 5% | - | **NS** |
| **Simultaneous vasopressors** | **30%** | **33%** | **14%** | **0.02** |
| **Inotropes** | | | | |
| **Dobutamine** | **49%** | 51% | 43% | **NS** |
| **Levosimendan** | **24%** | 22% | 31% | **NS** |
| **PDE3i** | **4%** | 4% | 5% | **NS** |
| **Simultaneous vasopressor and inotrope** | **55%** | 56% | 50% | **NS** |



*Tarvasmaki T et al. Crit Care Med 2016;20:208*

# Use of Inotropes and Vasopressors in the CardShock Study

- 94% of patients received vasoactive medication
- Initiated within the first 24 hours
- Vasopressors in 98% of cases
- Inotropes in 94% of cases
- Overall, associations with clinical presentation were modest
- NO marked associations with medical history, initial BP or HR, LVEF



*Tarvasmaki T et al. Crit Care Med 2016;20:208*

# Adrenaline Independent Predictor of Mortality

| Predictors of 90-day Mortality: Multivariable Logistic Regression Model | | | |
|---|---|---|---|
| Variable | OR | 95% CI | p |
| **Adrenaline use** | **5.3** | **1.88-14.7** | **0.002** |
| Age | 1.04 | 0.99-1.08 | 0.08 |
| History of MI | 3.4 | 1.3-8.9 | 0.01 |
| History of CABG | 12.1 | 1.8-79.1 | 0.005 |
| ACS etiology | 7.7 | 1.7-34.5 | 0.01 |
| Initial confusion | 2.1 | 0.8-5.6 | 0.1 |
| Systolic BP (per mmHg decrease) | 1.04 | 1.00-1.07 | 0.04 |
| LVEF (per % decrease) | 1.06 | 1.03-1.09 | <0.001 |
| Blood lactate (mmol/l increase) | 1.3 | 1.2-1.5 | <0.001 |



*Tarvasmaki T et al. Crit Care Med 2016;20:208*

# Adrenaline Independent Predictor of Mortality

## Survival curves for use of adrenaline










Propensity score: age, gender, medical history (myocardial infarction, coronary artery bypass graft surgery, hypertension, renal insufficiency), acute coronary syndrome as the etiology of cardiogenic shock, resuscitation prior to inclusion and initial presentation (confusion, blood lactate, creatinine, systolic blood pressure, sinus rhythm, and left ventricular ejection fraction).



*Tarvasmaki T et al. Crit Care Med 2016;20:208*

# Adrenaline Use Related to Deterioration in Cardiac and Renal Biomarkers in CS






*Tarvasmaki T et al. Crit Care Med 2016;20:208*

# Adrenaline Use Related to Deterioration in Cardiac and Renal Biomarkers in CS

- Overall 90-day mortality was 46% and significantly higher in adrenaline group vs other vasopressors: 90% vs 35%, p<0.001
- The strong association of adrenaline with increased mortality remained even after propensity score adjustment
- Adrenaline use was associated with markedly worse evolution of cardiac and renal biomarker levels over the initial 96 hours likely due to an increase in myocardial oxygen consumption, excessive vasoconstriction and/or direct organ toxic damage due to intense adrenergic stimulation
- This may, in part, explain significantly higher mortality among patients receiving adrenaline

# Inotropes: Why Have We Failed?

| | Dobutamine (n = 14) | Enoximone (n = 10) | Norepinephrine (n = 9) | P-value |
|---|---|---|---|---|
| HR, bpm | 84 [59–99] | 91 [78–107] | 101 [84–118] | NS |
| MAP, mmHg | 66 [60–71] | 68 [62–81] | 55 [51–58] | 0.006 |
| CVP, mmHg | 14 [11–17] | 14 [9–16] | 16 [12–19] | NS |
| PCWP, mmHg | 19 [16–25] | 23 [17–25] | 20 [17–27] | NS |
| MPAP, mmHg[a] | 27 [21–33] | 33 [28–37] | 28 [25–39] | NS |
| CI, $L.min^{-1}.m^{-2}$ | 2.2 [1.7–2.5] | 1.9 [1.7–3.2] | 2.6 [1.6–3.2] | NS |
| SVR, $dynes.sec.cm^{-5}$ | 1182 [743–1502] | 1057 [843–1246] | 837 [555–1031] | NS |
| SvO2, % | 64 [60–68] | 62 [56–71] | 67 [61–70] | NS |
| Lactate, $mmol.L^{-1}$ | 1.4 [1.1–4.6] | 1.3 [1.1–2.9] | 2.1 [1.1–2.8] | NS |
| Delta-T, °C | 6.6 [4.5–6.9] | 6.1 [4.3–7.5] | 6.2 [3.7–13.9] | NS |
| PCD, $mm.mm^{-2}$ | 9.3 [8.0–10.1] | 9.1 [8.9–10.2] | 9.8 [8.6–11.9] | NS |

30 CS patients (baseline parameters)



*Den Uil CA. PLoS One. 2014 Aug 1;9(8):e103978*

# Inotropes: Why Have We Failed?




Changes in perfused capillary density for individual patients



*Den Uil CA. PLoS One. 2014 Aug 1;9(8):e103978*

# Inotropes: Why Have We Failed?

Effects on Parameters of Macro- and Microcirculation

| | Dobutamine (n = 14) | Enoximone (n = 10) | Norepinephrine (n = 9) | P-value |
|---|---|---|---|---|
| ΔHR, bpm | +9 [0; +16]** | +4 [−11; +9] | +1 [−15; +4] | NS |
| ΔMAP, mmHg | +6 [−5; +21] | +8 [+1; +14] | +17 [+13; +32]** | NS |
| ΔCVP, mmHg | −1 [−3; +1] | −2 [−3; −1]* | +2 [−4; +4] | NS |
| ΔPCWP, mmHg | −2 [−4; −1]** | −2 [−3; −1]** | +5 [−1; +7] | NS |
| ΔMPAP, mmHg[a] | 0 [−3; +3] | −1 [−9; 0] | +4 [−1; +7] | NS |
| ΔCI, $L.min^{-1}.m^{-2}$ | +0.8 [+0.3; +1.4]** | +0.6 [−0.1; +1.5] | 0.0 [−0.5; +0.1] | 0.006 |
| ΔSVR, $dynes.sec.cm^{-5}$ | −201 [−623; +220] | −119 [−491; +175] | +390 [+237; +505]* | 0.03 |
| ΔSvO2, % | +6 [+2; +12]** | 0 [−3; +4] | 0 [−3; +6] | 0.04 |
| ΔLactate, $mmol.L^{-1}$ | −0.4 [−2.5; −0.1]** | 0.0 [−0.6; +0.2] | 0.0 [−0.2; +0.5] | NS |
| ΔDelta-T, °C | −0.4 [−0.8; 0] | −1.1 [−1.9; +0.6] | 0.0 [−2.2; +0.6] | NS |
| ΔPCD, $mm.mm^{-2}$ | +0.6 [−0.9; +2.3] | +2.0 [+0.5; +3.4]* | −0.4 [−3.3; 0.0] | 0.01 |



*Den Uil CA. PLoS One. 2014 Aug 1;9(8):e103978*

# What Do The ESC Guidelines Say?

WE ARE THE ESC

| Recommendations for inotropic and agents and vasopressors in patients with cardiogenic shock | | | |
|---|---|---|---|
| Short-term, i.v. infusion of inotropic agents may be considered in patients with hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status, to increase cardiac output, increase blood pressure, improve peripheral perfusion and maintain end-organ function. | IIb | C | |
| An intravenous infusion of levosimendan or a PDE III inhibitor may be considered to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypotension with subsequent hypoperfusion. | IIb | C | |
| Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern. | III | A | 556, 557 |



Acute Cardiovascular Care Association ACCA
A Registered Branch of the ESC

EUROPEAN SOCIETY OF CARDIOLOGY®

# What Do The ESC Guidelines Say?

| Recommendations for inotropic and agents and vasopressors in patients with cardiogenic shock | | | |
|---|---|---|---|
| A vasopressor (norepinephrine preferably) may be considered in patients who have cardiogenic shock, despite treatment with another inotrope, to increase blood pressure and vital organ perfusion. | IIb | B | 558 |
| It is recommended to monitor ECG and blood pressure when using inotropic agents and vasopressors, as they can cause arrhythmia, myocardial ischaemia, and in the case of levosimendan and PDE III inhibitors also hypotension. | I | C | 540, 559-563 |
| In such cases intra-arterial blood pressure measurement may be considered. | IIb? | C | |

# Take Home Messages

- Lack of evidence for clinical benefit for currently available inotropes and vasopressors
- In spite of this, virtually all cardiogenic shock patients receive treatment with cathecolamines usually a combination of inotrope and vasopressor
- Adrenaline use seems to be associated with increased mortality
- Trials to determine an evidence-based approach to vaso-active agent use are urgently needed
- Treatment tailored by assessment and optimization of microcirculation targets

www.santpau.org
asionis@santpau.cat

# Slide title here
# with space for two lines of text

- **Bullet point one, lorem ipsum dolor sit amet**
- **Bullet point two, lorem ipsum dolor sit amet**
  - Sub-bullet point one, lorem ipsum dolor sit amet
  - Sub-bullet point two, lorem ipsum dolor sit amet

- **Bullet point one, lorem ipsum dolor sit amet**
- **Bullet point two, lorem ipsum dolor sit amet**
  - Sub-bullet point one, lorem ipsum dolor sit amet
  - Sub-bullet point two, lorem ipsum dolor sit amet

# Targeted Medical Treatment in CS

Congestion (high or normal LVEDP)



Poor perfusion (low cardiac output)



- Increase CO and reduce LVEDP without worsening hypotension
- Improve tissue perfusion
- Improve survival

# Microcirculation

European Heart Journal (2010) **31**, 3032–3039
doi:10.1093/eurheartj/ehq324

CLINICAL RESEARCH
*Coronary heart disease*

## Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock

**Corstiaan A. den Uil[1]*, Wim K. Lagrand[2], Martin van der Ent[1], Lucia S.D. Jewbali[1], Jin M. Cheng[1], Peter E. Spronk[3], and Maarten L. Simoons[1]**

[1]Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Room V-017, s-Gravendijkwal 230, Rotterdam NL-3015 CE, The Netherlands; [2]Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands; and [3]Department of Intensive Care Medicine, Gelre Hospitals, Apeldoorn, The Netherlands

*Received 8 April 2010; revised 2 July 2010; accepted 23 July 2010; online publish-ahead-of-print 9 September 2010*

Sublingual perfused capillary density measured with sidestream dark-field imaging

*den Uil CA. Eur Heart Jour 2010;31:3032-3039*

# Microcirculation in Cardiogenic Shock

**Table 2** Baseline haemodynamic parameters

| | All patients ($n$ = 68) | PCD ≤ median[a] ($n$ = 35) | PCD > median[a] ($n$ = 33) | $P$-value |
|---|---|---|---|---|
| HR (b.p.m.) | 93 (72–104) | 92 (71–106) | 93 (72–104) | 0.80 |
| MAP (mmHg) | 69 (61–70) | 66 (58–70) | 70 (64–70) | 0.07 |
| CVP (mmHg) | 15 (12–18) | 16 (12–19) | 14 (13–16) | 0.23 |
| PCWP (mmHg)[b] | 21 (16–24) | 23 (18–25) | 18 (14–22) | 0.04 |
| MPAP (mmHg)[b] | 28 (24–34) | 30 (24–37) | 27 (24–30) | 0.18 |
| CI (L $min^{-1}m^{-2}$) | 2.5 (2.1–2.9) | 2.4 (1.8–2.9) | 2.7 (2.1–2.9) | 0.44 |
| CPI (W $m^{-2}$) | 0.35 (0.26–0.42) | 0.33 (0.24–0.39) | 0.38 (0.30–0.42) | 0.11 |
| SVR (dynes s $cm^{-5}$) | 1075 (825–1242) | 1075 (798–1237) | 1052 (850–1256) | 0.79 |
| $SvO_2$ (%) | 66 (61–73) | 65 (60–70) | 68 (62–75) | 0.12 |
| Lactate (mmol $L^{-1}$) | 2.8 (2.0–4.3) | 2.9 (1.8–4.5) | 2.8 (2.2–4.8) | 0.58 |

HR, heart rate; NS, non-significant; MAP, mean arterial pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index; CPI, cardiac power index; SVR, systemic vascular resistance; SvO2, central-venous oxygen saturation.
[a]Median PCD = 10.3 mm $mm^{-2}$.
[b]Data available in 48 (71%) of the patients.



*den Uil CA. Eur Heart Jour 2010;31:3032-3039*

# Low-dose Dopamine: Rose-AHF Trial









*Chen HH. JAMA 2013;310(23):2533-432013*

# Low-dose Dopamine: Rose-AHF Trial

No significant effect of dopamine on secondary endpoints:

- Decongestion
- Renal function
- Symptom relief

| Safety Drug Tolerance | Dopamine (n=122) | Placebo (n=119) | P-value |
|---|---|---|---|
| Study drug dose reduced of stopped because of hypotension | 0.9% | 10.4% | <0.001 |
| Study drug dose reduced or stopped because of tachycardia | 7.2% | 0.9% | <0.001 |
| Study drug discontinued due to any cause | 23% | 25% | 0.72 |



*Chen HH. JAMA 2013;310(23):2533-432013*

ORIGINAL CONTRIBUTION

Michael S. Cuffe, MD
Robert M. Califf, MD
Kirkwood F. Adams, Jr, MD
Raymond Benza, MD
Robert Bourge, MD
Wilson S. Colucci, MD
Barry M. Massie, MD
Christopher M. O'Connor, MD
Ileana Pina, MD
Rebecca Quigg, MD
Marc A. Silver, MD
Mihai Gheorghiade, MD
for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators

# Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure

## A Randomized Controlled Trial

*Cuffe MS. JAMA 2002;287:1541-7*

ORIGINAL CONTRIBUTION

Michael S. Gaffe, MD
Robert M. Califf, MD
Kirkwood F. Adams, Jr, MD
Raymond Benza, MD
Robert Bourge, MD
Wilson S. Colucci, MD
Barry M. Massie, MD
Christopher M. O'Connor, MD
Ileana Pina, MD
Rebecca Quigg, MD
Marc A. Silver, MD
Mihai Gheorghiade, MD
for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators

# Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure

## A Randomized Controlled Trial

**Table 4.** Primary Outcome and Hospitalization

| Outcome | Placebo (n = 472) | Milrinone (n = 477) | *P* Value |
|---|---|---|---|
| Days of hospitalization for cardiovascular causes within 60 days | | | |
| Median (IQR)* | 7 (4, 14) | 6 (4, 13) | .71 |
| Mean (SD) | 12.5 (14.0) | 12.3 (14.1) | |
| Days of hospitalization from infusion to initial discharge | | | |
| Median (IQR) | 5 (4, 8) | 5 (4, 7) | .99 |
| Mean (SD) | 7.0 (6.6) | 7.0 (6.2) | |
| Days of hospitalization for cardiovascular causes from discharge to 60 days | | | |
| Median (IQR) | 0 (0, 5) | 0 (0, 5) | .59 |
| Mean (SD) | 5.9 (12.5) | 5.7 (12.6) | |
| Days of hospitalization for any cause within 60 days | | | |
| Median (IQR) | 8 (4, 16) | 7 (4, 15) | .83 |
| Mean (SD) | 13.5 (14.4) | 13.4 (14.7) | |
| Death or readmission within 60 days, No./Total (%) | 164/464 (35.3) | 166/474 (35.0) | .92 |

*IQR indicates interquartile range.

**Table 6.** Adverse Events and Mortality*

| Adverse Event, No. (%) | Placebo (n = 472) | Milrinone (n = 477) | *P* Value |
|---|---|---|---|
| Treatment failure cause at 48 hours | 43/466 (9.2) | 97/470 (20.6) | <.001 |
| Progression of heart failure | 6.8 | 7.9 | .54 |
| Adverse event | 2.1 | 12.6 | <.001 |
| Events during index hospitalization | | | |
| Myocardial infarction | 2 (0.4) | 7 (1.5) | .18 |
| New atrial fibrillation or flutter | 7 (1.5) | 22 (4.6) | .004 |
| Ventricular tachycardia or fibrillation† | 7 (1.5) | 16 (3.4) | .06 |
| Sustained hypotension‡ | 15 (3.2) | 51 (10.7) | <.001 |
| Death | 11 (2.3) | 18 (3.8) | .19 |
| Events within 60 days | | | |
| Myocardial infarction | 5/448 (1.1) | 10/462 (2.2) | .21 |
| New atrial fibrillation or flutter | 16/446 (3.6) | 26/462 (5.6) | .14 |
| Ventricular tachycardia or fibrillation | 20/446 (4.5) | 23/461 (5.0) | .72 |
| Death | 41/463 (8.9) | 49/474 (10.3) | .41 |

*Total number of patients listed only when it varies from number randomized as shown.
†Reported by the investigator.
‡Defined as a systolic blood pressure below 80 mm Hg for more than 30 minutes, requiring intervention.

*Cuffe MS. JAMA 2002;287:1541-7*



Acute Cardiovascular Care Association ACCA
A Registered Branch of the ESC

EUROPEAN SOCIETY OF CARDIOLOGY®

# Dobutamine: Meta-analysis of 21 trials (632 AHF patients)




*Thackray S. Eur J Heart Fail. 2002;4(4):515-29*

# Milrinone vs Dobutamine or Dopamine




Pooled fixed effect on mortality OR 1.37 (95% CI 0.23 to 8.46)

*Thackray S. Eur J Heart Fail. 2002;4(4):515-29*

# CardShock Study






*Harjola V-P. Eur J Heart Fail. 2015;17:501*